Compare AbbVie Inc (ABBV) vs Wendys Co (WEN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Wendys Co — how do they compare? AbbVie Inc trades at $253.44 (market cap $449.91B), while Wendys Co trades at $7.39 (market cap $1.48B). The key difference: AbbVie Inc is far larger — about 304× Wendys Co's market cap, and Wendys Co pays the higher dividend (7.2%). Which is the better fit depends on your goals.
| ABBV | WEN | |
|---|---|---|
Market Cap | $449.91B | $1.48B |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $11.33 |
52-Week Low | $184.85 | $6.17 |
Enterprise Value | $513.38B | $5.30B |
Dividend Yield | 2.72% | 7.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.
The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.
Wendy's (WEN) trades at $7.78, down 9.53% today but up significantly from recent lows amid retail-driven momentum. The stock shows strong valuation metrics with P/E of 10.26 and P/S of 0.69, while recent earnings have consistently beaten expectations. Technical indicators suggest a bullish trend with key support at $7 and resistance at $8-9 levels. Recent news highlights digital sales growth and China expansion plans as potential catalysts.
The outlook remains mixed with fundamental challenges including declining net income margins (6.77% in 2025) and negative cash flow trends offset by attractive valuation and dividend yield. Key risks include weak U.S. traffic and cost inflation, while opportunities lie in international expansion and digital initiatives. Analyst consensus leans cautious with 65% hold ratings despite recent momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
